Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 17, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in share interests for specific individuals following the re-investment of dividends paid on January 4, 2007. The transaction price was GBP 13.70 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly reports compliance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Directors and managers increased their holdings via dividend re-investment at GBP 13.70 per share.
- Specific individuals notified include Dr M M Slaoui, Mr R Bondy, Mr M Dunoyer, Mr D Learmouth, Dr D Pulman, and Mr A Witty.
- The filing does not contain financial results or operational updates.